Multiple Myeloma (MM)
72
24
25
11
Key Insights
Highlights
Success Rate
65% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
6 terminated out of 72 trials
64.7%
-21.9% vs benchmark
6%
4 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 11 completed trials
Clinical Trials (72)
Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
Neurocognitive Trajectories After BCMA CAR-T
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
Rehabilitation Management for Patients With Multiple Myeloma
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma